21:38 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Small cell lung cancer Patient sample and cell culture studies suggest promoting IGFBP5 expression or inhibiting POU2F3 or IGF1R could help treat POU2F3-expressing small cell lung cancer (SCLC). In tumor samples from SCLC patients,...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Clinical News

AXL1717: Final Phase II data

Final data from the open-label, international Phase II AXL-003 trial in 99 evaluable patients with previously treated, locally advanced or metastatic NSCLC showed that twice-daily oral AXL1717 for 21 days per cycle missed the primary...
23:23 , Dec 27, 2013 |  BC Extra  |  Clinical News

Axelar's AXL1717 misses in Phase II NSCLC trial

Axelar AB (Solna, Sweden) said twice-daily oral AXL1717 missed the primary endpoint of improving the 12-week progression-free survival (PFS) rate vs. docetaxel in the Phase II AXL-003 trial to treat non-small cell lung cancer (NSCLC)...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Clinical News

AXL1717: Interim Phase II data

Interim data from the open-label, international Phase II AXL-003 trial in patients with previously treated, locally advanced or metastatic NSCLC showed that twice-daily 400 mg oral AXL1717 for 21 days per cycle led to a...
08:00 , Jan 28, 2013 |  BC Week In Review  |  Clinical News

AXL1717: Phase I/II started

Axelar said investigators at Rush University Medical Center began an open-label, U.S. Phase I/II trial of oral AXL1717 twice daily in 28-day cycles in about 30 patients with relapsed or progressive malignant astrocytomas. In the...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Clinical News

AXL1717: Phase II started

Axelar began an open-label Phase II trial comparing oral AXL1717 vs. docetaxel in about 140 patients with previously treated, locally advanced or metastatic NSCLC. Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) markets Taxotere docetaxel. Axelar...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Clinical News

AXL1717: Additional Phase I/II data

Additional data from the open-label, dose-escalation, Swedish Phase I/II AXL-001 trial in 49 patients with progressive solid tumors showed that the recommended Phase II dose of AXL1717 was 400 mg given twice daily in a...
07:00 , Apr 18, 2011 |  BC Week In Review  |  Clinical News

AXL1717: Interim Phase I/II data

Interim data from 35 patients in the Phase I portion of the ongoing, open-label, dose-escalation, Swedish Phase I/II AXL-001 trial showed that AXL1717 was well tolerated. Additionally, Axelar said an undisclosed recommended Phase II dose...
07:00 , Sep 13, 2010 |  BC Week In Review  |  Clinical News

AXL1717: Phase I/II data

Data from 4 heavily pretreated patients with progressive and advanced squamous non-small cell lung cancer (NSCLC) in an ongoing, open-label, dose-escalation Phase I/II trial showed that no patients developed any additional metastases after treatment with...
07:00 , May 18, 2009 |  BC Week In Review  |  Clinical News

AXL1717: Phase I/II data

Data from the first part of an ongoing, open-label, dose-escalation, Swedish Phase I/II trial in patients with terminal cancer showed that AXL1717 given twice daily for 1 day was well tolerated with no dose-limiting toxicities....